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ABSTRACT OF THESIS

RAPID NO• MEASURES IN RAT NUCLEUS ACCUMBENS AND FRONTAL
CORTEX FOLLOWING NASAL ADMINISTRATION OF NITROGLYCERIN
Nitric Oxide (NO) is a powerful endogenous free radical that has numerous
biological functions including vasodilation and serves as a post synaptic second
messenger in the central nervous system (CNS). Numerous studies implicate NO•
involvement in CNS disorders such as schizophrenia and drug abuse. These studies
address the direct in vivo determination of an FDA-approved NO• donor (nitroglycerin)
on extracellular levels of NO• in the frontal cortex and core of the nucleus accumbens in
a lightly anesthetized rat. State-of-the-art in vivo amperometric recording techniques
coupled with a novel 4-channel low noise pre-amplifier system and new generation
microelectrode arrays (MEAs) will be used to record extracellular levels of NO• at 100Hz
before and during nasal administration of either placebo (1) or nitroglycerin. This studies
will determine the feasibility of measuring NO• in the CNS while administering the NO•
donor nasally and determine the amplitude and kinetic time course effects of a nasally
delivered NO• donor in two rat brain areas, the frontal cortex and core of the nucleus
accumbens.
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Chapter One: Introduction and Outline
Nitric oxide
Nitric oxide (NO•) was recognized as a messenger molecule and chemically identical to
endothelium derived relaxing factor (EDRF) in 1988 (Tassorelli et al., 1999)(Garthwaite et al.,
1988). This substance was known to cause vasodilation in the vasculature but the structure was
unknown until 1988. Substances that act as nitric oxide donors, such as nitroglycerin and
molsidomine, have been utilized to treat angina pectoris and myocardial infarctions due to these
drugs abilities to lower blood pressure by relaxing blood vessels, allowing them to expand. Since
then, nitric oxide’s cellular pathways, physiological roles and pathological associations in the
brain have been elucidated. NO• has been implicated in disorders such as schizophrenia
(Bernstein et al., 2005), drug addiction (Herman, 1995), and cancer (Choudhari et al., 2013).
While further research is necessary to fully understand the role of NO• in these disorders, the role
of nitric oxide in excitotoxicity, long term potentiation (LTP) and synaptic plasticity is well
understood (Hardingham et al., 2013). One of the most well understood roles of NO• is in longterm potentiation (LTP) and synaptic plasticity. This occurs via the activation of NMDA channels
and postysnapic influx of Ca2+ that increases production of NO• (Hardingham et al., 2013). NO•
then acts as a retrograde secondary messenger and strengthen the synapse, which is the cellular
basis of learning.
Nitric oxide is unique as a transmitter in the CNS in that it is membrane-permeable and
cannot be sequestered in synaptic vesicles or spatially constrained by the synaptic cleft, as it can
rapidly diffuse away from its source site across cell membranes (Tassorelli et al. 1999). For this
reason it is not considered to be a neurotransmitter under the classical definition that restricts
neurotransmitters to chemical substances that are generated in advance, stored in synaptic
vesicles and, when released, diffuse and bind post-synaptically. The half-life of nitric oxide, in
vivo, was found to be on the order of half a second, which is relatively short when compared to
the traditional neurotransmitter dopamine, that has a half life of 2 minutes (Santos et al., 2011).
However, there are still thought to be two modes of transmission that NO• takes part in; local
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signaling, in the retrograde direction, and volume-type transmission wherein multiple
synchronous sources summate spatially (Garthwaite, 2018).
Synthesis and signaling
One way in which NO• is synthesized in the brain is by neuronal nitric oxide synthase
(nNOS) via increase in intracellular calcium (Ca2+) that follows the activation of N-methyl-Daspartate (NMDA) receptors (Santos et al., 2011). Glutamate, an excitatory neurotransmitter,
binds to and activates NMDA receptors to cause a localized increase in calcium through the
opening of calcium ion channels. Neuronal NOS is a calcium dependent enzyme and synthesizes
NO• from L-arginine (Garthwaite, 2018). While nNOS and epithelial derived nitric oxide
synthase (eNOS) are dependent on calcium for activation, inducible nitric oxide synthase (iNOS)
is not. Ca2+ has such an affinity for iNOS that its activity is not modulated by calcium signaling
but rather is mediated by cytokines (Hardingham et al., 2013). Additionally, the three types of
NOS isoforms are found in different areas of the brain. nNOS has been found in 1-2% of neurons
while eNOS has been localized to endothelial cells in the vasculature and to a small portion of
neurons in the hippocampus. Finally, iNOS has not been found to be expressed in the healthy
brain but has been seen in microglia and astrocytes following brain injury (Tassorelli et al., 1998).
It is important to note that there is no consistent pattern of expression of NOS in terms of being
localized to excitatory over inhibitory neurons. However, in some regions of the brain, such as the
cerbellum, nNOS is found in a majority of the cells (Garthwaite, 2018).
Nitric oxide’s mechanisms of action is known to be mediated through soluble gaunylyl
cyclase (sGC). SGC, a heterodimeric enzyme consisting of one alpha and one beta subunit, is the
most sensitive receptor of NO• (Hardingham et al., 2013). Two isoforms of alpha subunit exist
and have differing regional expression. For example the alpha1/beta1 heteromer is dominate in
the caudate-putamen and nucleus accumbens, a nucleus of interest in this study. The mechanism
of action of activation of sGC by NO• is mediated by conformational changes via the binding at
the heme site which enables sGC to convert GTP to cGMP (Hardingham et al., 2013). The
receptor does this with incredible 10,000 fold selectivity of NO• over O2, despite the two
molecules having similar anatomical structures. cGMP is then able to effect cGMP-activated
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protein kinases such as protein kinase G (PKG), initiating further downstream signaling events
including phosphorylation of effector proteins (Hardingham et al., 2013). A depiction of the
signaling pathways for NO• is found in FIGURE 1.2. Its important to note that signaling
mechanisms may be tissue specific and are not fully understood. Factors such as nNOS
concentration and local tissue media likely play a large role in the tissue specific role of nitric
oxide (Garthwaite, 2018), (Santos et al., 2011).
Decay and removal
The half-life of NO• in Wistar rats, via carbon-fiber microelectrodes and ceramic-based
microelectrode arrays, was determined to be 0.42 to 0.75 seconds (Santos et al., 2011). The ways
in which NO• consumption impose this short half-life remains unclear. While several enzymes
may contribute to NO• consumption in the brain, such as oxygen, cytochrome c oxidase,
superoxide radical and cytochrome-P450 oxidoreducatse, the full mechanism of CNS NO•
inactivation remains uncertain (Santos et al., 2011).
Through the understanding that nitric oxide follows an apparent first-order decay rate,
Santos et al. was able to study the role of red blood cells in NO• consumption through inducing
hemorrhagic shock in wistar rats. One hour of progressive blood withdrawal resulted in cardiac
arrest. During the hemorrhage, k, the first-order decay rate constant, was found to decrease. The
average decrease was 53+/-4.6%, which was twice the decrease seen in anoxia conditions. These
results suggest that circulating RBCs have a major role in governing nitric oxide dynamics in the
brain and likely act as the largest NO• sink in the vasculature. This study additionally reported on
the role of the vasculature in a neuroprotective auto regulatory loop whereby local ischemia
causes an increased concentration of NO•, which causes vasodilation which would decrease
ischemia and reduce the level of NO• that, in high concentrations, can be neurotoxic.
Scavenging of NO• by erythrocytes suggest NO• can easily diffuse through the vascular
wall (Santos et al., 2011). NO• small size and hydrophobic nature has supported the notion that
NO• diffuse freely in tissues. (Lancaster, 1997). While most molecules are retained in
extracellular space due to tortuosity, Santos et al. 2011 found that nitric oxide is not constrained
in the extracellular matrix in the same way most CNS signaling molecules are. Electrode
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recordings in agarose gel and in vivo in the rat brain found that NO• has a fast diffusion
coefficient of 2.2 x 10-5 cm2/s and additionally suggested a role of cell membranes and
hydrophobic structures as facilitating NO• diffusion.
The mechanism in which NO• is cleared by RBCs is well understood through the binding
of NO• to deoxygenated hemoglobin (Gow et al., 1999). NO• acts to nitrosylate hemoglobin
thiols or react with free superoxide molecules in solution. The enzyme superoxide dismutatse
(SOD) acts to eliminate superoxide in RBCs, increasing the concentration of Snitrosohemoglobin and nitrosylated hemes. SOD concentration is therefore able to regulate the
production of nitrosylated hemoglobin thiols. This pathway of NO• inactivation allows RBCs and
hemoglobin to act as a main regulator of NO• levels in vivo (Gow et al., 1999).
Nitroglycerin
Nitroglycerin, as depicted in FIGURE 1.1, has been utilized to treat angina pectoris and
myocardial infarctions since the 1970’s due to its vasodilating effects. Vasodilation leads to
increased coronary blood flow and reduction in cardiac pre- and post loads, treating the
aforementioned disorders. Nitroglycerin acts via the formation of the reactive intermediate nitric
oxide, who's cellular effect is described in the section titled “Nitric Oxide”. Nitroglycerin is
small, non-polar and highly lipophilic and, consequently, should have good permeability of the
blood brain barrier (BBB) to enter the CNS. While the complete mechanisms in which
nitroglycerin is converted to NO• in the brain are unknown, it is understood that the enzymes
glutatione-S-transferase and cytochrome P450, which are involved in biotransformation of
organic nitrates, are responsible for synthesis of NO• in the brain parenchyma (Tassorelli et al.,
1999). Studies have demonstrated that nitroglycerin is biotransformed mainly by sulphydryldependent enzymatic processes but can additionally be synthesized by sulphydryl-dependent nonenzymatic processes. Interestingly, application of nitroglycerin onto brain nuclei causes an
increase in the neuronal discharge rate. While, neurologically, nitroglycerin has been
demonstrated to induce migraines, it shows promise as a nitric oxide supplement to potentially
benefit disorders such as as drug addiction and schizophrenia. Additionally, nitroglycerin has
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already been FDA approved, minimizing the amount of time and financial resources that drug
researchers have to put forward in order to yield potential new medications.
Frontal Cortex
The frontal cortex has been implicated in many functional roles within the brain such as
decision making, language skills, emotion cognition and general consciousness (Teffer, 2012).
The frontal region of mammalian brains is functionally unique in that it is not defined by a
predominate input from any sensory system. Other cortical regions such as the occipital lobe and
parietal lobe can be attributed to sensory input of vision and proprioception, respectively (Klob,
1984). The frontal cortex has been associated with conditions like schizophrenia and drug
addiction through the mesocortical pathway (Ekhtiari & Paulus, 2016). This pathway is a tract of
dopaminergic neurons that connects the ventral tegmental area (VTA) with the pre-frontal cortex
(PFC). This pathway is highly associated with cognition and executive function. Increased
activation of this pathway is associated in drug addiction (Ekhtiari & Paulus, 2016). Conversely,
dysfunction of this pathway has been found to be implicated in the negative symptoms of
schizophrenia. Interestingly NO• has been implicated in pathologies of the frontal cortex through
studies such as Reif et al., 2006. This study found that a functional SNP in the promoter region of
nNOS is associated with schizophrenia and a worse frontal brain function.
Animal models, especially the use of rats, for research into frontal cortex injury and
function have been widely accepted in the research community. Despite large differences in the
relative volume of the frontal cortex across species of mammals, there appears to be a largely
conserved functions of the region (Kolb, 1984). This conservation of function is seen through
studies that found both lesion and insult to the prefrontal cortex of both primates and rodents
yielded similar sets of symptoms. These symptoms include poor performance on spatial learning
tasks, reduced facial expression and impaired performance on tasks requiring changes in behavior
(Kolb, 1984). These functional similarities suggest sufficient levels of translatability from rat
studies to humans to support rat models of frontal cortex research.
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Nucleus Accumbens
The nucleus accumbens (NAc) has long been dubbed the “pleasure center” of the brain.
This nucleus was first recognized as anatomically distinct from the more dorsal striatum by
Lennard Heimer in 1975. The role of the NAc has since been further elucidated and it is better
understood as a nucleus that aids in obtaining and directing attention towards motivationally
relevant goals by promoting behaviors that increase the likelihood of obtaining rewards (Floresco,
2015). The NAc is highly connected to other subcentral structures. It received inputs from the
prefrontal cortex, basolateral amygdala, hippocampus and VTA. Outputs of the NAc include the
ventral pallidum, hypothalamus and midbrain (Floresco, 2015). This strong interconnectedness
allows the region to integrate many different inputs to direct behavior towards attaining potential
rewards.
The NAc has been associated with pathologies such as schizophrenia and drug addiction
through the mesolimbic pathway. The mesolimbic pathway is a tract of dopaminergic neurons
that connects the ventral segmental area with the nucleus accumbens (Ritz & Kuhar, 1993). This
pathway is highly associated with human motivation, emotion and reward and its dysfunction is
associated with the positive symptoms of schizophrenia and drug addiction (Floresco, 2015).
Drug abuse is thought to cause increased dopamine neurotransmission in the mesolimbic
pathway, which reinforces the behavior of drug administration and contributes to the addictive
properties of many drugs (Ritz & Kuhar, 1993). Additionally, the nucleus accumbens, along with
other structures within the striatum, has been found to have some of the highest concentrations of
nNOS in the human brain and, consequently, is an area of intense interest in NO• research and
pathologies (Bernstein et al., 2005).
Intranasal Drug Administration
Nasal administration of drugs was perviously reserved only for local treatment of
disorders such as nasal allergy, nasal congestion and infections. Although the effect of nasally
administered drugs on the CNS has been recognized since before the cocaine boom of the 1980’s,
it wasn't until more recently that pharmaceutical drug companies have developed nasally
administered to treat CNS disorders. Examples include the use of intranasal (IN) morphine and
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ketamine, to treat pain, and apomorphine to treat erectile dysfunction. This route of
administration is expanding due to the limitation of off target effects and rapid onset (Illum,
2003).
Recently, drug development has branched into nasally administered vaccines, such as
influenza and the treatment of neurodegenerative disorders like Alzheimer’s disease (Illum,
2003). Through IN administration, researchers have reversed neurodegeneration and rescued
memory in a transgenic mouse model of Alzheimer’s (Hanson & Frey, 2008). Additionally, IN
insulin-like growth factor-I and erythropoietin have been shown to protect the brain against stroke
in animal models (Hanson & Frey, 2008). Additionally, IN insulin has been shown to improve
memory, attention and function in patients with Alzheimer’s disease without altering blood
glucose (Hanson & Frey, 2008). Here, I will discuss the ways in which drugs administered via the
nasal cavity are able to enter the CNS without crossing a selective filter such as the blood brain
barrier, the pros of nasal administration and considerations for the use of IN drugs in animal
models such as rats, which were utilized in this study.
Intranasal (IN) drug delivery has been utilized to circumvent the blood brain barrier
(BBB) that usually inhibits the transport of large, polar, hydrophilic molecules into the CNS
(Hanson & Frey, 2008). The BBB, at the cellular level, is generally referred to as a neuro-vascular
unit. This is comprised of endothelial cells of brain capillary walls, astrocyte end-feet that
surround the capillaries and pericytes (Hanson & Frey, 2008). These cell structures help to block
the import of unwanted compounds found in circulating blood through tight junctions, selective
protein transporters and even cassette protein transporters that can export unwanted compounds
once they have entered the CNS.
Pros of IN administration over general systemic administration of compounds includes
convenience, safety, cost and limitation of off-target effects. IN delivery limits the amount of the
compound that enters the systemic circulation (Hanson & Frey, 2008). This minimizes off-target,
possible negative side effects and the potential need to co-dose with peripheral inhibitors, as seen
in the case of LDOPA and its peripheral inhibitor Carbidopa. An example is that of IN
administered insulin which does not significantly effect blood glucose levels, demonstrating a
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lack of off-target effects of IN administered drugs (Hanson & Frey, 2008). However, it is
important to note that when drugs enter the nasal cavity, a portion still enters the blood stream and
can affect tissues and organs, causing off target effects. A portion of the drug in the blood stream
may be able to traverse into the CNS by penetrating the BBB. The percentage of compound that
will successfully penetrate the BBB is dependent on the properties of the compound. Large
molecular weight polar drugs such as peptides and proteins have relatively low permeability,
generally no more than 1% for peptides and 10% for small polar drugs (Stenslik et al., 2015).
Lipophilic drugs are generally well absorbed from the nasal cavity and boast bioavailability rates
approaching 100%. One example of such a compound is IN fentanyl, that boasts an impressive
bioavailability of ~80% (Illum, 2003).
The olfactory nerve pathway has long been described as the main pathway to the CNS
but recently the role of the trigeminal nerve in providing a direct connection with the CNS has
been elucidated. Both nerves innervate the nasal cavity and consequently provide a direct
connection to the CNS. A depiction of the innervation of the nasal cavity is seen in FIGURE 1.3.
It is interesting to note that the trigeminal pathway has been associated with drug delivery to more
caudal brain regions and the spinal cord when compared to the olfactory nerve pathway. For a
drug to reach the CNS from the nasal cavity it has to transverse the nasal olfactory epithelium
and, depending on the path taken, the brain’s arachnoid membrane (Illum, 2000). There are three
suggested pathways that a drug can take to cross the olfactory epithelium, pictured in FIGURE
1.4. First, the transcellular pathway utilizes receptor mediated endocytosis, fluid phase

endocytosis or passive diffusion to allow drugs to cross the olfactory region’s cellular layer,
specifically sustentacular cells (a type of support cell) (Illum, 2000). Next, paracellular transport
is possible via tight junctions found between sustentacular cells and olfactory neurons. Finally,
there is transport of compounds by the olfactory nerve pathway. In this mode the drug is taken up
by a neuron via endocytosis or pinocytosis and then transported by axonal transport to the
olfactory bulb. This pathway is thought to be relatively slow compared to the extracellular
delivery pathways (Illum, 2000).
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There are many considerations to take into account with IN drug development. The nasal
mucociliary clearance system has a half-life in the order of 15-20 minutes (Illum, 2003). This can
decrease the absorption and bioavailability of the compound in the CNS, especially for drugs that
are not easily absorbed across the nasal membrane (Illum, 2003). This issue can be resolved, in
part, through the implantation of co-administered compounds that effect nasal absorption. These
compounds, which include bile salts, work by either delaying the mucociliary clearance or
increasing paracellular transport by opening the tight junctions between the epithelial cells (Illum,
2003). Compounds such as starch and chitosan have been shown to slow mucociliary clearance
and consequently increase the bioavailability of the drugs in the CNS (Illum, 2003).
While no compound was co-administered in this study, the chemical properties of
nitroglycerin, the nitric oxide donor utilized in this study, shape the compound as a potentially
membrane permeable drug. Nitroglycerin has a relatively low molecular weight, is non-polar, and
lipophilic, which is expected to enhance its ability to diffuse through sustentacular cells in the
olfactory region of the nasal cavity (Tassorelli et al., 1999). A pro for the utilization of nasal
administration of nitroglycerin is the potential limitation of off-target effect of peripheral
vasodilation, which results in decreased blood pressure.
It is important to take into consideration the species difference between humans and
animal models of IN administration of drugs. The olfactory region of mouse, rat and non-human
primate animal models cover a much larger proportion of the nasal cavity as compared to
humans. Furthermore, in rat IN studies, the rat is commonly placed on its back during the study,
which can increase the contact of the drug with the olfactory region. While this position was not
used due to the MEA head-cap and FAST system attachment, the modified prone position that
was utilized could potentially increase the amount of contact the test articles, nitroglycerin and
miglyol, had with the olfactory region of the animal. These two considerations foster rat model
studies as yielding more pronounced olfactory transport of drugs than in humans (Illum, 2000).
Thesis Outline
This study was utilized to determine the feasibility of measuring extracellular NO• in the
CNS while administering a NO• donor, nitroglycerin, nasally and determining the amplitude and
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kinetic time course effects of a nasal delivered NO• donor in two rat brain areas, the frontal cortex
and the nucleus accumbens. This section, Chapter One, covered the relevant background and
current understanding of the synthesis, signaling and clearance of nitric oxide in the mammalian
brain. Chapter Two will cover the use of microelectrode arrays (MEAs) as a measurement of
nitric oxide in the extracellular space in two aforementioned subcortical structures. This includes
a look into MEA fabrication, mPD exclusion layer coating and calibration carried out prior to
electrode implementation. Chapter Three will delve into the experimental design, materials,
surgical methods, experimental methods and statistical analysis used in this study. Finally,
Chapter Four will cover the main findings of this study, considerations, and future directions.
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FIGURE 1.1: STRUCTURE OF NITROGLYCERIN
Shown above is a depiction of nitroglycerin as seen in Tassorelli et al., 1999. It is easy to
see how, when present in solution, nitroglycerin is non-polar with all three nitrate groups
canceling each other out to leave a relatively non-polar compound free of large dipole
interactions. This molecule is highly lipophilic and has a relatively low molecular weight.
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FIGURE 1.2: NEURONAL SIGNALING PATHWAYS OF NITRIC OXIDE
Seen above is a schematic of the signaling pathway of nitric oxide as seen in Hardingham
et al, 2013. This image depicts the signaling cascade from nNOS, shown here as NOS1, to the
production of NO•, binding to sGC and production of cGMP that can cause multiple down stream
effects. Not discussed in the corresponding section is the role of nitrosothiol groups in
maintaining neuronal homeostasis and pre-synaptic plasticity.
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FIGURE 1.3: HUMAN NASAL CAVITY
The image above is depicted in Illum et al. 2000. This image depicts the olfactory bulb
and its associated sensory neuron bundles that penetrate through the cribriform plate to the nasal
cavity. This figure also depicts the high degree of innervation throughout the nasal cavity and
facial region. This betters the visual understanding of the role that trigeminal nerve plays in nasal
drug delivery alongside the olfactory nerve. It is also helpful to note the proportion of the nasal
cavity that the olfactory region (below the olfactory bulb) occupies, as this is discussed in the
considerations section of “Intranasal Drug Administration”.
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FIGURE 1.4: OLFACTORY NERVE AND OLFACTORY REGION CELL TYPES
Depicted are the various types of cells that support the olfactory region of the nasal
cavity. Support cells, seen here as sustaining cells, are an integral part of the transcellular and
paracellular pathways of IN drug uptake. Olfactory receptor cells are bipolar neurons which are
seen here as “olfactory cell”. These cells give rise to a single non-myelinated axon which forms
large bundles with other olfactory cells and penetrate through the basal membrane and,
subsequently, through the holes in the cribriform plate. These fibers then synapse in the
glomeruli, which reside near the surface of the olfactory bulb (Illum et al., 2000).
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Chapter Two: MEA Electrochemistry, Fabrication and Calibration
MEA Fabrication
Enzyme-based multisite microelectrode arrays are mass fabricated using
photolithographic methods. This allows for mass production of reproducible recording surfaces as
small as 5-10 µm (Hascup et al. 2006). A 2.5 cm x 2.5 cm x 125 µm thick ceramic wafer serves as
a common substrate for the MEAS. Ceramic is used since it reduces the cross-talk from adjacent
connecting lines and is strong and rigid (Hascup et al. 2007). Thin Films Technology, Inc.,
(Buellton, California) was the manufacturer of the four channel MEAs utilized in this study.
Copper wires are soldered onto the paddle, one for each corresponding platinum (PT) recording
site. Gold sockets are soldered to the other ends of the copper wire, which are inserted into a
miniature black connector along with a miniature silver/silver chloride wire. Five-minute epoxy is
applied to hold the apparatus together and keep the ceramic tip of the MEA parallel to the
miniature black connector for stereotaxic placement. At this point, the entire apparatus is now
referred to a pedestal MEA (Hascup et al. 2007). The MEAs were delivered to the Gerhardt lab
pre-fabricated, only requiring reference electrode coating, mPD coating and calibration prior to
being utilized in the study. An image of an MEA pedestal and rendering of the electrode tip can
be found in FIGURE 2.1.
Solutions Used
Solutions used includes 0.05 M Phosphate Buffered Saline solution (PBS lite). The pH of
the solution was tested and determined to be a desired 7.4.5mM. m-Phenylenediamine (mw 181.1
Aldrich Chemistry) was made fresh daily due to the solutions tendency to oxidize within a few
hours of synthesis. Additionally, 20 mM sodium nitrate solution and 8.8 mM hydrogen peroxide,
2.0 mM dopamine were used.
diethylenetriamine (DETA)/ nitric oxide adduct
A 20 mM solution of DETA was utilized. This solution takes at least an hour to generate a
stable concentration of NO• so the solution was allowed to sit for the minimum amount of time to
generate a final NO• concentration of 0.2 mM before being used in a calibration experiment.
5 mM m-Phenylenediamine
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5mM m-Phenylenediamine (mw 181.1 Aldrich Chemistry) was made fresh daily due to
the solutions tendency to oxidize quickly (within a few hours of synthesis). First, nitrogen gas
was bubbled through 100 mL of 0.05 M PBS solution for no less than 20 minutes. See PBS lite
solution recipe above. Then 0.0905 grams of mPD (Sigma-Aldrich) was added to the 100 mL of
PBS. This solution was inverted in the volumetric flask three times to mix. Solution was
temporarily stored with paraffin film (Parafilm) until used to coat the MEA electrodes.
mPD Coating
5mM m-Phenylenediamine was made fresh daily as detailed in the “Solutions Used” section. A
glass reference Ag/AgCl electrode, that is reserved just for plating, was placed in the beaker and
attached to the Quanteon 20pA/mV headstage (Quanteon, Lexington, KY). The MEA was then
attached to the headstage using the connector and the tip of the electrode was submerged in the
mPD solution. Electroplater software was used (Quanteon, Lexington, KY). The P-P amplitude
was set to 0.25, the offset was set to -0.5. Frequency was set to 0.05 Hz. This resulted in a wave
pattern that generated three triangular waves per second. The Electroplater system was allowed to
run for 15 minutes to sufficiently coat the electrode in mPD. The same electrode system was run
in reverse chronoamperometry via the FAST system (Quanteon, Lexington, KY). The system was
set to run at -0.55V vs. Ag/AgCl. This reverse current was utilized to partially remove some of
the accumulated mPD. This process has been found to not negatively effect the role of the
exclusion layer but simply boost nitric oxide selectivity (Friedemann et al., 1996). The mPD
solution was exchanged for PBS and allowed to run for 5 minutes. After the completion of this
reverse current, the MEA was removed from the headstage apparatus and stored at room
temperature in a covered, light-proof container.
Ag/AgCl Reference Coating
While larger glass Ag/AgCl reference electrodes are suitable for mPD
electropolymerization and microelectrode calibration, this reference electrode is too large for
many biological applications. For this reason, a smaller Ag/AgCl reference electrode is fabricated
and adhered to the head-cap of the MEA. In this section I will describe the process of coating this
Ag wire with chloride (Cl). First, the ends of the silver wire were stripped of Teflon coating. The
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head cap was then placed into a clamp and the exposed end of the wire was placed into a 1 M
HCl saturated with NaCl. A Pt wire acts as the counter electrode and was also placed into the
solution, not touching the silver reference electrode wire. Alligator clips, that were powered by a
9V DC adapter, were attached to the electrode head-cap and the end of the platinum wire. The
applied potential then attracted Cl- ions to the silver wire to form AgCl, thus yielding the Ag/
AgCl reference electrode. This phenomena was observed as reactive bubbling on the surface of
the Pt wire. Current was sustained until there was an absence of new bubble formation, which
signaled the end of the reaction. This generally took less than one minute in time. A depiction of
reference electrode coating is seen in FIGURE 2.2.
Calibration
Calibration is utilized to test substance selectivity and normalize the coated sites for selfreferencing recordings. Using the FAST recording system, a nitric oxide donor (DETA) was the
analyte of interest. MPD coating on the MEA, the exclusion layer, worked to select against
measuring nitrate by physically blocking it from interacting with any of the four channels.
Sodium nitrate was utilized as the interferent. Hydrogen peroxide (H2O2) was utilized as the
positive control and displayed the sensitivity of the MEA. The analyte concentration was 0.2 µM
and the interferent concentration was 250 µM. Recordings took place at 0.6V vs. Ag/AgCl
applied voltage and recordings were measured at 100Hz. P200s and P1000s (Rainin
micropipette), and corresponding 200mL and 1000mL pipette tips, were used during calibration
as well as later during experimentation. Four compounds — an interferent (nitrate), analyte
(nitiric oxide) and two test substances (DA and H2O2) — were applied to the PBS solution
throughout the course of the calibration. A table of the order and volume of added solutions can
be found in TABLE 2.1. All solutions were stored in a refrigerator at 5 degrees celsius.
A 50 milliliter glass beaker was filled with 40 mL of 0.05 M PBS solution. This beaker
was placed in a plastic holder which rested upon a battery operated, portable magnetic stir plate
(Cole and Parmer portable magnetic stirrer). A battery operated stir plate was used to reduce
potential AC (60Hz) current that can affect the recordings. A magnetic stir bar was added to the
PBS solution and was set to stir slowly to avoid the formation of a vortex in the solution. A glass
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Ag/AgCl reference electrode is placed in the buffer solution. The microelectrode was attached to
a 2pA/mV Quanteon headstage. The end of the Ag/AgCl reference wire is also plugged into the
headstage. Finally, the microelectrode tip was partially lowered into the PBS solution
(approximately a few millimeters). A photograph of the calibration system can be seen in
FIGURE 2.4. After initial system settings were established on the FAST software, the recording

system applied a potential of +0.6 V versus the Ag/AgCl reference to the microelectrode
recording surfaces. The current was allowed to reach a stable baseline. This generally took
anywhere from 10-15 minutes time. Once the baseline was achieved, it was ‘marked’ on the
FAST computer system.
Following the establishment of a baseline voltage, 500 µl of nitrate was added for a final
beaker concentration of 250 µM. When a new stable baseline was reached, the interferent was
marked by the user. Next, three 40µl additions of 40 µM nitric oxide were added for final buffer
concentrations of 40, 80 and 120 µl nitric oxide for a final concentration of 0.2 µM. Analyte
marks were recorded after each addition to create the calibration curve. Following these three
additions of analyte, 40 µl of 2 mM DA (2 mM, final beaker concentration) was added to the
solution as a test substance and marked. Finally, 40 µl of 8.8 mM hydrogen peroxide was added
to the solution to confirm microelectrode sensitivity and the addition was allowed to reach a new
stable baseline and marked. A figure of the desired recording is found in FIGURE 2.5. After
marking the second test substance baseline, the calibration was ended and resultant selectivity and
sensitivity were analyzed. The MEA was removed from the apparatus and was stored at room
temperature. The PBS solution that contained all four experimental solutions was discarded prior
to starting another calibration.
Dopamine was utilized to further insure the integrity of the electrode and peroxide was
used to examine the MEA over all responsiveness. The additions of test substances did not factor
into calculating the standard curve for the analyte of interest since they followed the application
of analyte. Chemicals used in vivo should be tested in vitro to ensure that they are not
electrochemically active in vitro prior to its local application near the Pt recording sites during
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experimentation. This ensures that in vitro or in vivo analyte concentration changes are from the
analyte of interest rather than due to local application of drugs.
The calculations for selectivity ratios for nitric oxide over sodium nitrate, slope
(microelectrode sensitivity for nitric oxide), limit of detection (LOD) and linearity (R2) are found
below. A poor linearity, calculated by R2 is rarely seen with good microelectrodes. Since the
microelectrode array fabrication procedure is highly reproducible, nitric oxide responses are
extremely linear and resulted in linear regression curve fits with R2 greater than or equal to 0.99.
Sensitivity of the microelectrode refers to how well the electrode can measure the change in nitric
oxide. The sensitivity is calculated by the slope of the three additions of nitric oxide. This number
is used to equate a change in current to a change in nitric oxide concentration. The slope is also
utilized to calculate limits of detection which we have designated as the most important criteria
for determining if a microelectrode is satisfactory for use. We utilize limits of detection (LOD) to
select microelectrodes because slopes can be misleading. LOD refers to the limit of detection for
the microelectrodes defined as the analyte concentration that yields an electrode response that is
equivalent to three times the background noise of the recording system. This is calculated by
taking the root mean squared of the background signal multiplied by 3 then divided by the slope
((RMS background signal X 3)/slope of NO• signal). This is the lowest detectable change in
analyte concentration that can not be attributed to noise, in other words the lowest detectable
change that is significant. Microelectrodes with LODs that are lower than the response they
expect to observe were selected. This is generally less than or equal to 1uM.
Selectivity refers to a ratio of the microelectrodes sensitivity to nitric oxide over
interferents such as nitrate. It is calculated by dividing the nitric oxide slope by the nitrate slope.
The slope of the interferent is simply one point, the single addition of nitrate as compared to the
baseline signal, but this has been found to be sufficient for selectivity calculations. A
microelectrode with a selectivity of 100:1 means that for every 100 molecules measured 99 are
nitric oxide while only 1 is nitrate. A selectivity of 100:1 ensures that the microelectrode is 99%
effective at blocking nitrate. Selectivity ratios of 100:1 or greater were ideal.
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FIGURE 2.1: MEA SIZE AND DESIGN
Above is an image of the microelectrode array used in this study. Ceramic-based MEAs
were assembled and prepared by Thin Films Technology, INC., (Buellton, California). In this
image, the MEA is compared to a standard metric ruler shown in centimeters. The red arrow
indicates the tip of the MEA that contains the four channel electrodes. The Ag/AgCl reference
wire is seen extending to the 5 cm mark below the ceramic electrode tip. It is possible to see the
whitened tip of the reference electrode that has undergone the reaction with HCl to yield a white
Ag/AgCl coating on the end of the wire. An image of the four channels is shown to the right.
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FIGURE 2.2: MPD AS AN EXCLUSION LAYER
MPD was utilized as an exclusion layer for the detection of dopamine in vivo. This image
shows the selective exclusion of compounds such as DA and NO3- , substances that could skew
the accurate recording of NO• in vivo. Note that NO• and H2O2 are able to cross the mPD
exclusion layer, reduce and donate one and two electrons, respectively, to the positively charged
platinum (PT) sensor. The following balanced electrochemical reaction of the reduction of NO•
on a metal surface, such as Pt, at a positive electrode potential. This reaction demonstrates that
the oxidation of NO• in this experiment proceeds via a three-electron oxidation mechanism
(Privett et al., 2010). A simplified equation is as follows: NO• + OH + H2O —> NO3- + 3e- + 3H
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FIGURE 2.3: Ag/AgCl REFERENCE ELECTRODE COATING
Depicted is a beaker of 1 M HCL saturated with NaCl, the MEA electrode being held by a metal
three-prong clamp (indicated by the red arrow, left) and a platinum (Pt) wire (indicated by the
blue arrow, right). The MEA and Pt wire were attached to a 9V DC adapter fitted with alligator
clips that were hooked to electrical wires as depicted. The reaction was run to yield an Ag/AgCl
reference wire Once the reaction was run to completion and NO• further bubbling was observed
on the Ag reference wire, the current was cut off. After coating, the ends of the silver wire were
observed against a high-contrast black background to ensure that a bright, white Ag/AgCl
reference wire was produced. MEAs were then returned to dark storage in boxes and were stored
at room temperature.
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Sequence of
addition

Role

Volume/
Concentration

Solution

number of
additions

1 Interferent

500mL/250uM

Nitrate

1

2 Analyte

40mL/6.2uM

Nitric Oxide

3

3 Test substance

40mL

DA

1

4 Test substance

40mL

H2O2

1

TABLE 2.1: CALIBRATION SOLUTIONS
This table depicts the order and volume of the solutions added throughout the course of electrode
calibration. All agents were added after a baseline was established and “marked” on the FAST
system. The first additive, nitrate, was added following a 15 minute stabilization period that
allowed the electrode to establish a baseline under the applied voltage.
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FIGURE 2.4: CALIBRATION SET-UP
Depicted above is the complete set-up of a calibration experiment. The plastic stand sits atop the
battery powered magnetic stir platform. A 50mL beakers placed in the stand and filled with 40
mL of PBS lite solution. A miniature stir bar was added to the beaker and was utilized to circulate
the added calibration compounds. The MEA is shown attached to the Quanteon 2pA/mV
headstage, shown left. The silver reference electrode is shown on the right of the beaker and was
attached to the reference attachment point on the headstage. Not shown is the connection to the
FAST system, displayed on a desktop computer or the test compounds utilized during a
calibration.
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NO3-

FIGURE 2.5: NITRIC OXIDE CALIBRATION GRAPH
This image was adapted from Hascup et al. 2006. The additions follow the order and
volume noted in TABLE 2.1. This graph depicts the desired current observed from the
subsequent additions of analytes over time. Note the lack of response after the addition of nitrate
(denoted NO3-). This is followed by three 40ml additions of the nitric oxide solution (NO). The
dashed line indicates the slope of the analyte addition, showing compounding activation with
each addition. The sensitivity of the microelectrode is inferred by the slope of the three analyte
additions. The graph shown here has strong linearity and correlation between subsequent
additions and detection of NO.
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Chapter Three: Materials and Methods
Animals
A total of 10 (5 per brain region) research naïve male Wistar rats (F344) 1-2 months old
weighing ~150-175 (Envigo) were needed for this study. Upon arrival at the University of
Kentucky, individual cage-card and research chart were created and the animals were allowed to
go through a standard acclimation/quarantine period while being housed in the DLAR facility.
After the 7 days acclimation period animals were implanted with an electronic ID transponder.
The Wistar rat was chosen as the test system because of its established usefulness and
acceptance as a rat strain. It is also the phylogenetically lowest species that provides adequate
size, tissue and anatomy for the proposed studies. The number of animals used is the minimum
necessary to obtain scientifically valid results. The total number of animals used in this study was
14, not 10, due to varied adverse outcomes that resulted in animals not completing the full threepart experiment. The study does not unnecessarily duplicate any previous work and alternatives to
the use of live animals have been considered. Procedures used in this study have been designed to
avoid or minimize discomfort, distress or pain in the animals. Animals that experienced severe
chronic pain or distress that cannot be relieved would have been painlessly euthanized in
consultation with the University of Kentucky veterinary staff and Study Director. The Study
Sponsors would have been advised by the University of Kentucky in a timely manner of all
circumstances that could have lead to this action.
Experimental Design
Two sets of in vivo electrochemical studies with 5 rats per arm (10 animals total) were
carried out in order to evaluate the effects of nasal administration of NO• donor on extracellular
NO• levels in 2 brain regions, the nucleus accumbens and frontal cortex. Each animal (n=10, 5
per brain region) received 3 treatments.
Due to the nature of these experiments and analyses, it was expected that the experiments
be conducted for 3 weeks per animal (2 animals per week on study) with analyses performed on
the data after completion. We estimated that the in-life of the recordings would span a total of 14
weeks and final analyses, histology and data analyses would take an addition 4-6 weeks; total
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study in-life was estimated to be 24 weeks (6 months) including study start-up, which involves
animal protocol approvals. The timeline was adjusted as study modifications were needed
throughout the course of experimentation (when requested and approved by the study sponsor in
consultation with the testing facility). All efforts were taken to maintain the study timeline,
although secondary to any needed actions to maintain data quality and reproducibility.
Randomization and Blinding
Animals were randomly assigned into 2 groups (each brain region). Animals received
placebo (negative control) and NO• donor (nitroglycerin at 2 different doses) and the test and
control articles labeled A, B and C were administered via nasal administration such that Study 1
and Study 2 had a total of 10 animals that received the 3 treatments. Test and control articles,
although identified alphabetically A, B and C by label, are coded by the study director so that
experiments and analyses are performed with study staff blinded to the test groups. All animals
received all three treatments, following the randomization scheme depicted in TABLE 3.1.
Test and Control Articles
The sponsor provided the NG formulations. The Study Director transferred materials to
vials and prepared the saline and SNP solutions daily. The Study Director provided the 3 solutions
(blinded) labeled A, B and C to the PI on the day of use.
Recipes:
A) Negative control (Miglyol)
B) Nitroglycerin (NG) 50 mg/ml (dissolved in Miglyol); 15 mg/kg
C) Nitroglycerin (NG) 50 mg/ml (dissolved in Miglyol); 10 mg/kg
(Nitroglycerin solution dissolved in Miglyol, 50 mg/ml - Novasep)
Test and control articles were stored as indicated by Novasep Synthesis.
Any residual test and control articles were stored at 5 degrees C in a refrigerator until after the
final report has been signed/approved by the study director in consultation with the study sponsor,
at which time residual samples may be discarded. The weight of the animals, on average, was
slightly higher than the originally anticipated maximum value of 400 grams. Animal weight
during experimentation ranged from 366-454 grams. The concentration of the test article was
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adjusted accordingly by the study director to ensure the same volume of TA was delivered during
experimentation.
Nasal Administration
The test and control articles were administered via nasal delivery with animals under
isoflurane sedation, as described in Stenslik et al., 2015. Administration was via P200
micropipette tips. Further information and considerations of intranasal administration can be
found in the corresponding section.
Controls
Controls are intended to show the effect of procedure or experimental design in the
absence of the agent of interest. In this study, the control was Miglyol.
Husbandry and Veterinary care
The procedures described in this section were performed in accordance with the
appropriate standard operating procedures in use by the University of Kentucky Division of
Laboratory Animal Resources (DLAR). The animals were given an acclimation period of
approximately one week. All adverse consequences resulting from administration of the test
article and collection procedures as well as subsequent treatments provided by a qualified
member of the veterinary staff were documented in the study records. While adverse
consequences are described in the section labeled, “Adverse Outcomes”, no subsequent
treatments were provided by a member of the veterinary staff and consequently not recorded.
Animal Housing
All animals in the study were housed in the University of Kentucky DLAR facility, which
is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC). While on study, the animals were housed in plastic boxes and maintained on a
12-hour light/12-hour dark cycle in temperature-controlled and humidity-controlled rooms,
ranging approximately from 64˚F to 84˚F and 30% to 70%, respectively. Each housing unit was
identified with a cage card indicating, but not limited to: animal ID number, species, sex, vendor
and IACUC protocol number. A variety of toys were provided to the animals for enrichment.
Dietary materials
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Each animal was fed a standard, commercial diet ad libitum. Municipal tap water,
purified by reverse osmosis was available ad libitum via an automated watering system.
Additionally, animals were provided supplemental snacks upon completion of each of the three
parts of experimentation. This treat was either Cheeto cheese puffs or Pops sugar puff cereal.
There were no contaminants suspected in either the diet or purified water that would be expected
to have an effect upon the outcome of the study.
Procedures
Surgical Procedure

Surgical procedures were carried out based on the University of Kentucky DLAR
standards of aseptic anesthetized animal surgery. Pre-surgical procedures were as follow:
Isoflurane (Attane Isofulurane, USP liquid for inhalation) was replenished in the
vaporizer and a heated water pad (Gaymar Industries, Inc, TP3E), connected to a water
bath (Gaymar Industries, Inc, T/Pump, TP500), was set to 40 degrees celsius to maintain
an animal body temperature of 37 degrees celsius. Animals were sedated in an induction
chamber at 3.0-3.5% Isoflurane. Animals were then transferred to a stereotaxic frame
(Koph Instruments) and secured into place with a palate clip and ear bars. Both the
induction chamber and stereotaxic frame received vaporized Isoflurane from a Patterson
Veterinary Vaporizer. The palate clip of the stereotaxic frame was set at -2.3 cm and ear
bars entered the ear canal and were set at an average of -7.0 to -8.0 cm on either side to
secure the head in a flat plane. Anesthetic was reduced to 2.0-2.5% for the remainder of
the surgery. Animals were administered Rymadyl (5mg/mL) at 5mg/kg to mitigate pain
from surgery. The animals’ eyes were lubricated with lubricant eye ointment (Lubrifresh
P.M (sterile) to prevent dry eyes or debris from entering their eyes. Animal heads were
shaved near the intended site of incision from between the eyes to past the approximate
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location of lambda. Betadine was then applied locally to the shaved area and two sterile
alcohol prep pad wipes (Fisherbrand medium) followed to ensure a sterile site of incision.
An inch long incision was made in between the eyes using a 10 blade scalpel
(Feather Surgical Blade and Handle stainless steel) that was extended approximately an
inch caudally. Fascia was removed from the top of the skull and stainless-steel clamps
were used to secure the fascia away from the surgical field. Cautery was used as needed
to limit bleeding. Additionally, 0.9% saline solution and gauze pads were used to clear
the surgical field of blood and debris as needed throughout the procedure. Bregma was
identified and marked using a permanent marker (Sharpie), helping divide the surgical
field into four identifiable quadrants. Three burr holes were made using a Dremel 107 bit
(2.4mm) on a Froedom MH-170 surgical drill. These three holes, intended for screws,
were placed into all of the quadrants except for the right rostral quadrant, which was
reserved for S2 electrode implantation. An additional burr hole was made in the quadrant
diagonal from the electrode quadrant. This hole was utilized later for placement of the
reference electrode. A diagram of the schematic of the burr holes as seen on a dorsal view
of the rat skull can be found in FIGURE 1. Screws were removed from their storage in
isopropyl alcohol, rinsed with 0.9% saline solution and then screwed into the three burr
holes. A rat’s skull thickness can be anywhere from 0.5-1.0 mm (Paxino & Charles, 1998)
and the screw threads were 2.0 mm. Once threaded, the screws were screwed in about
1mm to leave approximately 1.0 mm exposed above the skull.
The burr hole position for the electrode was approximated from bregma. The two
subcortical areas of interest were measured as noted in TABLE 3.2 found in the supplemental
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images. All measurements were based on the atlas (Paxino & Charles, 1998) and were

measured from the electrode tip, attached to the stereotaxic frame, from the center of
bregma. Abbreviations for electrode implantation coordinates are Anterior-Posterior
(AP), Medial-Lateral (ML), Dorsoventral (DV). Coordinates were for nucleus acuumbens
were AP: -1.0, ML: -2.2, DV: +7.8 and AP: -3.2, ML -0.8 and DV: +5.5 for the frontal
cortex. Forceps were used to ensure that the burr hole was smooth and perpendicular at
all points, so the electrode would not touch any portion of the skull that was not clearly
visible from the dorsal surface of the skull. The electrode was placed on the stereotaxic
frame arm and the tip of the electrode was measured to a subcortical region from bregma
using AP and ML measurements. Adjustments to the burr hole were made on an asneeded basis. This includes removing the electrode from the surgical field, via moving
the stereotaxic frame arm, to drill further to enlarge the burr hole.
Once the electrode was aligned and deemed ready to be implanted, the Ag/AgCl
reference electrode was placed into the reference burr hole. The electrode was implanted
under the skull so that it sat parallel to the skull to minimize localized neuronal damage
from the electrode implantation. The reference wire was then wrapped around the two
posterior screws to secure it in place. The electrode was then implanted into the cortical
area of interest. Electrode placements were confirmed post-mortem through cryostat
brain sectioning (Gerhardt et al. 2018). Once the electrode was placed at the proper DV
location, superglue and activator (Kwik-Fix project glue, Kwik-Fix activator) was applied
to the electrode tip to secure the electrode into place. From this point, additional glue and
activator was used to build a mound around the S2 apparatus. Clips were removed from
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the surrounding fascia and the skin surrounding the surgical field was adhered to the S2
system.
The animal was taken off anesthesia, removed from the stereotaxic frame and
returned to its housing unit that was placed on a heating pad. The heating pad helped
maintain the animal’s body temperature while regaining consciousness. Animals were
monitored for three days post surgery. Daily weights were taken. Rymadyl was
administered intramuscular daily in doses of 5 mg/kg. After this recovery period, animals
were returned to the DLAR animal facility for housing for the next three weeks. Animals
were run through the first study seven days after the surgical implantation date.
Experimental Procedure

Seven days after implantation of the MEA pedestals, rats were connected to a
FAST Mark IV electrochemical recording system, which is controlled by a Labview/
Matlab software interface for real-time measures. Two animals were run simultaneously
and always through the same computer and induction chamber throughout the course of
the full experiment. Experiments were conducted no sooner than seven days following
surgery and no sooner than five days following the previous experiment. This ensured
sufficient amount of time for the animal to eliminate any test agents from their body
(Gerhardt, Greg A, et al. 2018.). Experimentation took, on average, five hours. This time
includes retrieving animals from the animal storage facility, induction and both rounds of
test article administration. Experimentation had two sections. The first sections
recordings took place at +0.6 V vs. Ag/AgCl. A baseline measure was recorded for 30
minutes before the nasal administration of test articles. Recordings continued for an

32

additional 1.5 hour. The recording were then reset to +0.2 V vs. Ag/AgCl and baseline
was recorded for another 30 minutes. The designated test article was delivered by nasal
delivery under sedation to determine possible noise and/or interference to the NO•
signals. Recordings were continued for an additional 1.5 hours.
Prior to experimentation, animals were first induced in an induction chamber at
3.0-3.5% Isoflurane (Attane Isoflurane, USP liquid for inhalation). Once anesthetized,
animals were weighed and attached to the head-stage of the Fast Analytical Sensing
Technology (FAST) computer-controlled potentiostat system (FAST; Quanteon,
Lexington, KY). The animals were positioned in a modified prone position with their
heads angled upward towards the corner of the induction chamber to allow for easy nasal
administration of the test articles. A depiction of this positioning is seen in FIGURE 3.2.
Once properly positioned and deemed sufficiently sedated, Isoflurane levels were
reduced to 2.0% for the remainder of the first 30 minute baseline recordings. Test articles
were retrieved from storage at 5 degrees celsius. Test and control articles were all made
by the study director within 48 hours of experimentation and blinded to the experimenter
through designations article A, B and C (Gerhardt et al. 2018). After the 30 minutes of
recording a baseline signal, the test or control articles were administered by micropipette
tips (Rainin micropipette). 125 µl of test agent was administered over a 5 to 6 minute
period. 12.5 µl was administered per nostril with one minute wait periods in between the
end of each article administration. This means that 25 µl was administered five times
over an average of six minutes.
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After nasal administration, recordings were continued for another 90 minutes
under light sedation of 1.5-1.75% Isoflurane. Upon completion of the +0.6 V vs. Ag/
AgCl recording, animals were maintained under sedation and run through the same
experimental procedures at +0.2 V vs. Ag/AgCl, which was repeated over the following
two hours. This recording was utilized to administer the designated test or control article
again to determine possible noise and/or interference to the NO• signals recording for the
final 90 minutes of the two hour total recording time. At the end of experimentation,
animals were removed from anesthesia and returned to their home cages. The cages were
placed on a heating pad to help maintain a normal body temperature until regaining
consciousness. Animals were then returned to the University of Kentucky DLAR facility
for a five day (minimum) anesthesia washout period. The remaining 2 of the 3 articles
were administered over the course of the next two weeks, one per week. Thus, animals
received 3 treatments over the 15-21 day period (Gerhardt et al. 2018).
Administration of test articles resulted in a variety of observable behaviors including
change in respiration rate and depth. Often, following the second round of nasal administration,
noticeable difficulty in breathing was observed. This was considered a potentially severe adverse
outcome. Adverse outcomes are further documented in the corresponding subsection.
Additionally, eye blink and reflexive head movements were observed during nasal administration
in most animals. This was considered a consequential outcome from TA delivery and not an
adverse outcome. Animals that displayed significant head jerk activity as a reflexive response to
nasal administration of the test article were not repositioned to the modified prone position until
at least 10 minutes following that round of nasal administration. This precaution was taken to
ensure minimal interference with the FAST recording system during the minutes following TA
administration.
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Euthanization
At the completion of the testing of the 3 treatment recording days, rats were euthanized
by Isoflurane sedation utilizing sustained level Isoflurane (4-5%) for up to five minutes until
normal breathing was notably disrupted. Animals were subsequently decapitated, placed in a
labeled bag and stored in a -18 degree freezer. Brains were removed later and sliced using a rat
brain mold to confirm the location of the MEAs (Gerhardt et al. 2018).

Adverse Outcomes
Throughout the course of this experiment four animals did not finish experimentation
and, consequently, new animals had to go through the acclimation period, surgery, recovery time
and then run through the entire three part experiment. This group of animals includes three
animals from the nucleus accumbens group and one animal from the frontal cortex arm of the
study. The adverse outcomes included the loss of the animal’s head cap, generally caused by the
animal’s own self mutilation by bumping its head, and death during experimentation. A more
detailed list of fatal events are found in TABLE 3.3. The adverse event of head-caps falling off
was determined to be caused by expired project glue (Kwik-Fix instant bond as well as adhesive).
Following replacement of project glue with non-expired product, the issues of lost head-caps seen
in animals #1 and #2 was not seen in any subsequent animals. The second fatal issue seen in
Animals #5 and #9, death during experimentation, was determined to be due to poor circulation
and aspiration of the test article during experimentation. After implementation of a heating pad
for animal #8 (experiment 3) and animals #5 and #10, this issue of death due to insufficient
respiration was not observed again. Animals that displayed severe respiratory disturbance
following the second round of test article administration were moved to a full prone position to
ease their breathing. This movement was made no sooner than 10 minutes following the end of
the TA administration.
Non-fatal adverse outcomes were also observed throughout the course of
experimentation. Mild respiratory distress was the most prevalent and most concerning adverse
event. Changes in breathing were closely monitored during and following nasal administration of
the test article. Generally, significant changes in respiratory rate and depth were observed
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following the second round of nasal administration of the test article during the 0.6 V vs Ag/AgCl
recording period. Other non-fatal adverse outcomes included, but were not limited to difficulty
regaining consciousness post experimentation. This was defined as any time greater than 20
minutes after being removed from anesthesia. This event was observed in <5 animals.

Record Retention
Modifications in the study design were only made with verbal or written consent of the
Study Director. Verbal authorization must be documented in the raw data and followed by a
written protocol amendment within 10 business days. All amendments or deviations to the
approved study protocol were documented, signed by the Study Director, dated, and maintained
with the study protocol . All amendments to the approved study protocol were also approved by
the Sponsor. After the final report is approved by the Study Director, all raw data and specimens
relating to this study will be archived for up to 1 year. The test facility archives staff will contact
the Sponsor after 1 year following report finalization to determine disposition of the archived
materials (except for the raw data on durable media, study correspondence, and the copy of the
final report). Portions of the study conducted by the sponsor or sponsor’s designee will be
archived in the storage facilities of the sponsor or sponsor’s designee (Gerhardt et al. 2018).
Data Analysis
All data sets were analyzed by our Matlab based analysis system that involves FFT
filtering, boxcar averages and averaging of data from the 4 sites of the MEAs prior to averaging
of responses from the different animals. The low voltage measures were used to identify any
interferences. Our detection limits in vitro are estimated to be in the 10-20 nanomolar range
(Santos et al. 2011). In vivo results can vary due to physiological changes that may occur at the
higher doses of test article administration. The studies were based in groups of 5 due to power
analysis requirements. Power calculations using an α=0.05, β=0.10, and a detectable difference of
30-40% from baseline for the measures predict the necessary sample size of n=5 for the proposed
studies. All data were analyzed using an Analysis of Variance (ANOVA) followed by appropriate
post-hoc comparisons. Final data analyses is focused on the effects of the 3 treatments on
maximum extracellular NO• ([NO]max) and kinetic data of the signals involving Trise, T1/2, T100
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(all in minutes). Note: these are discovery studies with no guarantee that the doses and route of
administration of the NO• test article would produce detectable levels of NO• (Gerhardt et al.
2018).
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Treatment Day
Animal

1

2

3

1

A

B

C

2

B

C

A

3

A

C

B

4

B

C

A

5

A

B

C

TABLE 3.1: RANDOMIZATION OF TREATMENT ORDER
This table depicts the randomization of treatment groups. The randomization order was
followed for both groups (the two brain regions). As noted in the corresponding section, test or
control articles were all made by the study director within 48 hours of experimentation and
blinded to the experimenter through designations of article A, B and C (Gerhardt et al. 2018). Test
and control articles are described by composition and concentration in the section labeled test and
control articles. The experimenter was blinded to which article corresponded to each compound.
This ensured that the order of test article administration did not confound results.
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FIGURE 3.1: DORSAL SKULL VIEW
Depicted in the image above is the view of a rat skull as seen in The Rat Brain: in
Stereotaxic Coordinates by George Paxino and Charles Watson. This image has been modified
from the original text to include color coded dots that indicate the approximate location of burr
holes that were made during the S2 implementation surgery. Yellow dots indicate the locations of
screws and the green dot indicates the location of the Ag/AgCl reference electrode. The Ag/AgCl
reference electrode burr hole is placed in the contralateral quadrant to minimize any noise or
electrical interference from the S2 electrode and provide the best possible reference signal. The
red dot indicates the location of the S2 electrode burr hole for the nucleus accumbens and the blue
dot indicates the location of the S2 electrode implantation burr hole for measuring local nitric
oxide levels in the rat frontal cortex. Note: all burr hole placements shown are approximate.
During surgical implantation of the MEA, the two different regions for electrode placement were
measured using the stereotaxic arm.
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Nucleus Accumbens:
AP -1.0
ML -2.2
DV +7.8
Frontal Cortex:
AP -3.2
ML -0.8
DV +5.5

TABLE 3.2: SUBCORTICAL COORDINATES
Depicted above is a table of the A/P, M/L and D/V for the two subcortical areas of
interest. All values are listed in millimeters. Subcortical locations were referenced based on
(Paxino & Charles, 1998). These locations were measured using the stereotaxic frame (Koph
Instruments) from bregma, as noted in (Paxino & Charles, 1998). The tip of the MEA was
attached to the stereotaxic frame arm and placed directly above bregma and AP and ML
measurements were made using this arm. Once the electrode was above the pre-drilled burr hole,
the MEA was ensured to fit properly in the opening. If adjustments were necessary, the MEA on
the arm was removed from the surgical field, necessary adjustments were made to the burr hole to
ensure proper location of MEA placement. Then the MEA was again measured from bregma. DV
was reset once the MEA tip came into contact with the dura. Once placement was correct, the
process of applying the project glue and drying it with the Kwik-Fix activator was initiated.
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Animal number

Number of
experiments
completed

Reason for not
completing
experimentation

Additional notes

Animal #1

1

lost head-cap

second animal #1
completed full
experiment

Animal #2

1

lost head-cap

second animal #2
completed full
experiment 11/8/18

Animal #5

1

death during
experiment 2 due to
respiratory distress

second animal #5
completed full
experiment
12/17/18

Animal #9

1

death during
experiment 2 due to
respiratory distress

second animal #9
completed full
experimentation
2/19

TABLE 3.3: ADVERSE OUTCOMES LEADING TO PREMATURE
EXPERIMENTATION TERMINATION
Two adverse events resulted in premature death or euthanization. This included the loss
of the animal’s head-cap, the top of the MEA that held the attachment points to the four channel
electrode as well as anchored the reference electrode wire. In one case, the head-cap popped off
from excess pressure experienced from the attachment to the FAST system. In the other case, the
animal, through self mutilation, caused the release of the head-cap from the skull by breaking the
adhesive. Both animals were euthanized following the loss of the head-cap. Two animals died
during experimentation from what was dubbed respiratory distress due to aspiration of the test
article. The test articles administered to animals #5 and #9 were B and C, respectively. Both of
these test articles contained nitroglycerin, although in different concentrations, but the chemical
properties of nitroglycerin, as compared to miglyol, could potentially account for this outcome.
However, this issue was resolved and not observed again after the implementation of heating pads
during experimentation. This was utilized to help normalize circulation and body temperature
during the experimentation of these anesthetized animals.
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Floor of induction chamber

FIGURE 3.2: EXPERIMENTAL POSITIONING
The animal position during experimentation is depicted in the image (viewed from below
the animal). Animals were positioned in this modified prone position to allow for easy nasal
administration through the nostrils due to being exposed and easily accessible by micropipette
tips. Shown in dashes is the induction chamber that the animals were placed in during
experimentation. This rectangular box allowed the animals to rest on their belly while their heads
were placed at a sharp upward angle to facilitate the nasal administration of test articles. During
experimentation, the animal rested both of its cheeks on either side of the corner of the induction
chamber.
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Chapter Four: Results and Discussion
Results
In this study we used amperometric recording techniques coupled with a 4-channel low
noise pre-amplifier system and new generation microelectrode arrays (MEAs) with high spatial
(µm) and temporal (100 Hz) resolution to explore in vivo effects of an FDA-approved NO• donor
(nitroglycerin) on extracellular levels of NO• in the frontal cortex and nucleus accumbens of
lightly anesthetized Wistar rats following intranasal administration. FAST recording system was
utilized to record the full four hour experiment. An example of a tracing produced from the
experiment can be seen in FIGURE 4.1.
Frontal Cortex
The results of the frontal cortex, as seen in FIGURE 4.2, do not show any significant
difference in measured extracellular NO• levels between the three treatment groups, myglol, 10
mg/kg nitroglycerin (NG) and 15 mg/kg nitroglycerin. The average value of the area under the
curve (AUC) was ~1,000, ~1,000 and ~1,000 for myglol, NG10mg/kg and NG 15mg/kg,
respectively. While the 95% does include 0 for all compounds except the 15mg/kg Nitroglycerin
dose, meaning the nasal administration of the other two compounds could, theoretically, not cause
a localized extracellular increase in NO• in the frontal cortex at all, it is likely with increased
sample size (N) that there would be significant difference from 0 for all three compounds.
However, there is no significant difference between the increased extracellular concentration of
NO• following nasal administration of NG as compared to myglol.
Nucleus Accumbens
The results of the nucleus accumbens, as seen in FIGURE 4.3, do not show any
significant difference in measured extracellular NO• levels between the three treatment groups,
myglol,10 mg/kg nitroglycerin and 15 mg/kg nitroglycerin. The average value AUC was much
higher than for the frontal cortex at ~4,000, ~5,000 and ~4,000 for myglol, NG10mg/kg and NG
15mg/kg, respectively. While the 95% does include 0, meaning the nasal administration of all
three compounds could not cause a change in extracellular NO• in the nucleus accumbens, it is
likely with increased sample size (N) that there would be significant difference from 0 for all
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three compounds. While there is no significant difference between the increased extracellular
concentration of NO• following nasal administration of NG as compared to myglol, it is
interesting to note that the average AUC values of all three test articles are approximately five
times higher than those measured in the frontal cortex.
Conclusions
This study was unable to conclude there was a significant difference in the level of
extracellular nitric oxide measured in the rat frontal cortex and nucleus accumbens following the
nasal administration of nitroglycerin, a widely accepted nitric oxide donor, when compared to the
placebo of Miglyol. It does suggest that nasal administration of myglol may cause a significant
increase in extracellular nitric oxide in the two subcortical areas of interest. This could be due to a
physiological response to nasal administration. This theory suggest that, regardless of the
compound, nasally administered substances cause a response in animals that causes increased
extracellular NO• in the two subcortical areas. A way to test this theory is to add an additional
control of saline, as myglol itself has to be ruled out from causing the observed effect.
There are many hypotheses as to why nitroglycerin did not significantly effect the
extracellular concentration of NO•. Firstly, there is the chance that NG was not able to enter the
CNS through the nasally administered drug route described in the section, “Intranasal drug
administration”. While the chemical properties of nitroglycerin suggests the drug should be able
to cross the sustentacular cells via receptor mediated endocytosis and enter the brain,
nitroglycerin may not easy utilize this so called transcellular pathway. Additionally, the drug may
not be able to enter the brain via transversing tight junctions of sustentacular cells in the
paracellular pathway. It was already demonstrated in previous research that, despite following all
of Lipinksi’s rules except for the number of H bond donors, nitroglycerin does not seem to
effectively cross the blood brain barrier. See section, “Intraperitoneal Studies” for more
information. A final possible reason as to why nitroglycerin is not able to cause increased
extracellular NO• is that, despite entering the CNS properly via the aforementioned pathways,
once nitroglycerin is oxidized, the NO• generated is rapidly inactivated by the brain’s vasculature
as described in the section “Decay and Removal”.
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Interestingly, average AUC measured in the nucleus accumbens was, on average, 5 times
greater than the frontal cortex. One interpretation of these results includes the notion that there is
a higher NOS concentration in the nucleus accumbens as compared to other cortical structures
(Vincent and Kimura, 1992). A study conducted by Vincent and Kimura selectively stained the rat
brain for NADPH-diaphorase. This enzyme provides a specific histochemical marker for the
production of NO•. Their results showed that the striatum exhibited some of the heaviest staining.
Additionally, in humans, the highest levels of nNOS were measured in the nucleus accumbens,
along with other structures such as the cerebellar cortex and septal area (Bernstein et al., 2005).
This notion that there is a high NOS concentration in the nucleus accumbens is supported by the
results we reported in this study. However, further research needs to be conducted within this area
to fully elucidate the basal concentration of NOS and NO• signaling throughout the brain.
Future Directions
Intraperitoneal Studies
A previous study looked into the effects of three nitric oxide donors on extracellular NO•
concentrations in the frontal cortex and nucleus accumbens following intraperitoneal
administration. While none of the NO• donors were found to have a significant effect, as seen in
TABLE 4.3 and TABLE 4.4, one drug, molsidomine, showed promise as causing significant

changes in extracellular NO• in the two subcortical areas, particularly the frontal cortex. It is an
important consideration that these studies were conducted in awake wistar rats, as compared to
the light sedation used in the nitroglycerin study. It is additionally interesting to note the
differences in the average AUC for the two studies. For the frontal cortex averages for the AUC
were ~800 for molsidomine, ~300 for nitroglycerin, ~200 for saline and ~200 for myglol-saline.
Similar averages were found in the nucleus accumbens with the exception of myglol-saline and
molsidomine which both had an average AUC of ~1,000. It is interesting to note that, within the
intraperitoneal study alone, there was no large difference found between the average AUC in the
frontal cortex as compared to the nucleus accumbens. This is an important difference between this
study and the reported intranasal study.
Molsidomine
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Molsidomine is a nitric oxide donor with the chemical formula of C9H14N4O4 (Aronson &
Meyler, 2016). This compound is FDA approved to treat angina pectoris, acute myocardial
infarction, congestive heart failure and pulmonary hypertension in oral and injectable forms
(Rosenkranz et al., 1996). The prodrug is metabolized to SIN-1, an active metabolite, and NO
through hydrolysis and decarboxylation in the liver and has a half-life of 1 to 2 hours. The
bioavailability through oral administration is 44-59%. This compound, as displayed in the
section, “Intraperitoneal Studies” is a possible candidate for intranasal administration. While the
IP studies did not yield a significant result for Molsidomine, an increase in the concentration of
drug administered, number of animals run through the study and potential greater uptake of the
compound through intranasal means (as compared to systemic administration) could yield
significant results. Furthermore, Molsidomine follows all of Lipinski’s rule of 5 with sufficiently
low molecular weight, LogP, H bond donor atoms and H bond receptor atoms. This is interesting
considering that nitroglycerin does not follow one of Lipinski’s rules by having too many H bond
donor atoms.
A large concerns with continuing intranasal research of NO• donor prodrugs include the
rate at which the prodrug is converted to NO• in the brain parenchyma. It is quite plausible that
the drug is converted to metabolites, SIN-1 in the case of molsidomine, and NO• prior to reaching
the target cortical structures and therefore it can not cause a localized increase in extracellular
NO• concentrations. Instead, the NO• is potentially rapidly inactivated by the brain’s dense
vasculature system as NO• has been suggested to rapidly diffuse through epithelial cells to enter
the vasculature (Santos et al., 2011).
Intranasal Nitroglycerin
The results of this study support nitroglycerin, without co-administration with another
compound, as a poor candidate to continue further intranasal drug development studies. The lack
of a significant difference, as compared to myglol, suggests that there is insufficient nitric oxide
donated from nitroglycerin reaching the target cortical structures. As stated previously, there are
multiple way in which this lack of increased extracellular NO• could occur. Other issues that arise
with any intranasal drug is the lack of specificity. Distribution of nasally administered compounds
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can vary depending on the chemical properties of the drug. While a large proportion of the
compound can remain in the olfactory region (olfactory nerve and bulb), a lack of permeability
into deep cortical structures is not likely the cause of not statistically significant results since
permeability into the striatum and substantia nigra has been observed for nasally administered
DNSP-11 (Stenslik et al., 2015). A final consideration is the understood role of NO• donors in
causing headaches and migraines. If an intranasal NO• donor was to enter stage 1 clinical, it is
likely there would be mild to moderate side effects of headaches. This could interfere with drug
dosage and tolerability.
In the future, alternative NO• donor molecules, such as molsidomine, which have shown
promise for significantly altering extracellular NO• in the nucleus accumbens and especially in
the frontal cortex, should be considered for further investigation. I propose an identical study be
run with an additional test agent of saline, to control for the effects of myglol, as well as
behavioral and cognitive testing before and after drug administration to scan for behavioral
changes in the animals that could translate to side effect profiles and tolerability in humans.
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TABLE 4.1: EXPERIMENTAL TRACING, ANIMAL 6 NG-10
The above tracing shows the data yielded from an experiment. The graph depicts time on
the Y axis and the change in the concentration of NO• in µM on the Y axis. This particular tracing
is from animal 6 with the test article nitroglycerin 10mg/kg dosage. Where the two dashed lines
intersect is the point at which nasal administration began. The tracing continues throughout the
end of the experiment. While this example shows remarkable changes in the µM concentration of
NO•, in total over the 5 animals, no statistically =significant result was seen.
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TABLE 4.2: AUC OF TEST ARTICLES IN THE FRONTAL CORTEX
Depicted above is the recorded AUC in the frontal cortex for the three treatments in this
study: myglol, nitroglycerin 10mg/kg (NG-10) and nitroglycerin 15mg/kg (NG-15). the 15mg/kg
dosage of nitroglycerin was the only compound to not contain the value “0” in its 95% CI.
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TABLE 4.3: AUC OF TEST ARTICLES IN THE NUCLEUS ACCUMBENS
Depicted above is the recorded AUC in the nucleus accumbens for the three treatments in
this study: myglol, nitroglycerin 10mg/kg (NG-10) and nitroglycerin 15mg/kg (NG-15). None of
the compounds elicited significant changes in extracellular nitric oxide concentrations, as seen by
the 95% CI that contain the AUC value “0”.
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TABLE 4.4: EXTRACELLULAR NO• LEVELS IN THE FRONTAL CORTEX
FOLLOWING INTRAPERITONEAL ADMINISTRATION OF NO• DONORS
Depicted above is the recorded AUC in the frontal cortex for the five treatments
in this study: molsidomine (MD), nitroglycerin (NG), saline (S), myglol-saline (M-S) and SNP, a
known NO• donor. None of the compounds elicited significant changes in extracellular nitric
oxide concentrations, as seen by the 95% CI that contain the AUC value “0”. However, it is
interesting to note how much larger the average AUC for molsidomine was as compared to the
other NO• donors, nitroglycerin and SNP.
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TABLE 4.5: EXTRACELLULAR NO• LEVELS IN THE NUCLEUS ACCUMBENS
FOLLOWING INTRAPERITONEAL ADMINISTRATION OF NO• DONORS
Depicted above is the recorded AUC in the frontal cortex for the five treatments
in this study: molsidomine (MD), nitroglycerin (NG), saline (S), myglol-saline (M-S) and SNP, a
known NO• donor. None of the compounds elicited significant changes in extracellular nitric
oxide concentrations, as seen by the 95% CI that contain the AUC value “0”. It is interesting to
note that molsidomine and myglol-saline had higher average AUCs as compared to the other three
test articles.

52

References
Bernstein, Hans-Gert, et al. “The Many Faces of Nitric Oxide in Schizophrenia. A Review.”
Schizophrenia Research, vol. 78, no. 1, 2005, pp. 69–86., doi:10.1016/j.schres.2005.05.019.
Choudhari, Sheetal Korde, et al. “Nitric Oxide and Cancer: a Review.” World Journal of Surgical
Oncology, vol. 11, no. 1, 2013, doi:10.1186/1477-7819-11-118.
Ekhtiari, Hamed, and Martin P. Paulus. Neuroscience for Addiction Medicine: from Prevention to
Rehabilitation. Elsevier, 2016.
Floresco, Stan B. “The Nucleus Accumbens: An Interface Between Cognition, Emotion, and
Action.” Annual Review of Psychology, vol. 66, no. 1, 2015, pp. 25–52., doi:10.1146/annurevpsych-010213-115159.
Friedemann, Marilyn N., et al. “o-Phenylenediamine-Modified Carbon Fiber Electrodes for the
Detection of Nitric Oxide.” Analytical Chemistry, vol. 68, no. 15, 1996, pp. 2621–2628., doi:
10.1021/ac960093w.
Garthwaite, J. “Nitric Oxide Signaling in the Central Nervous System.” Annual Review of
Physiology, vol. 57, no. 1, 1995, pp. 683–706., doi:10.1146/annurev.physiol.57.1.683.
Garthwaite, John. “NO as a Multimodal Transmitter in the Brain: Discovery and Current Status.”
British Journal of Pharmacology, vol. 176, no. 2, 2018, pp. 197–211., doi:10.1111/bph.14532.
Gerhardt, Greg A, et al. Rapid NO Measures in Rat Nucleus Accumbens and Frontal Cortex
Following Nasal Administration. BDD Berolina Drug Development GmbH, 2018.
Gow, A. J., et al. “The Oxyhemoglobin Reaction of Nitric Oxide.” Proceedings of the National
Academy of Sciences, vol. 96, no. 16, 1999, pp. 9027–9032., doi:10.1073/pnas.96.16.9027.
Hardingham, Neil, et al. “The Role of Nitric Oxide in Pre-Synaptic Plasticity and Homeostasis.”
Frontiers in Cellular Neuroscience, vol. 7, 2013, doi:10.3389/fncel.2013.00190.
Hascup, K. N., et al. “Second-by-Second Measures of L-Glutamate in the Prefrontal Cortex and
Striatum of Freely Moving Mice.” Journal of Pharmacology and Experimental Therapeutics, vol.
324, no. 2, 2007, pp. 725–731., doi:10.1124/jpet.107.131698.
Hascup, Kevin, et al. “Second-by-Second Measures of L-Glutamate and Other Neurotransmitters
Using Enzyme-Based Microelectrode Arrays.” Frontiers in Neuroengineering Series
Electrochemical Methods for Neuroscience, 2006, pp. 407–450., doi:
10.1201/9781420005868.ch19.
Herman, Barbara H, et al. “The Effects of NMDA Receptor Antagonists and Nitric Oxide
Synthase Inhibitors on Opioid Tolerance and Withdrawal.” Neuropsychopharmacology, vol. 13,
no. 4, 1995, pp. 269–293., doi:10.1038/sj.npp.1380298.
Illum, Lisbeth. “Nasal Drug Delivery—Possibilities, Problems and Solutions.” Journal of
Controlled Release, vol. 87, no. 1-3, 2003, pp. 187–198., doi:10.1016/s0168-3659(02)00363-2.
Illum, Lisbeth. “Transport of Drugs from the Nasal Cavity to the Central Nervous System.”
European Journal of Pharmaceutical Sciences, vol. 11, no. 1, 2000, pp. 1–18., doi:10.1016/
s0928-0987(00)00087-7.

53

Kolb, B. “Functions of the Frontal Cortex of the Rat: A Comparative Review.” Brain Research
Reviews, vol. 8, no. 1, 1984, pp. 65–98., doi:10.1016/0165-0173(84)90018-3.
“Molsidomine.” Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug
Reactions and Interactions, by J. K. Aronson and L. Meyler, Elsevier, 2016, pp. 1085–1085.
Paxino, George, and Charles Watson. The Rat Brain: in Sterotaxic Coordinates. Academic Press,
1998.
Prast, H., et al. “Nitric Oxide-Induced Release of Acetylcholine in the Nucleus Accumbens: Role
of Cyclic GMP, Glutamate, and GABA.” Journal of Neurochemistry, vol. 71, no. 1, 2002, pp.
266–273., doi:10.1046/j.1471-4159.1998.71010266.x.
Privett, Benjamin J., et al. “ChemInform Abstract: Electrochemical Nitric Oxide Sensors for
Physiological Measurements.” ChemInform, vol. 41, no. 42, 2010, doi:10.1002/chin.201042277.
Reif, A, et al. “A Neuronal Nitric Oxide Synthase (NOS-I) Haplotype Associated with
Schizophrenia Modifies Prefrontal Cortex Function.” Molecular Psychiatry, vol. 11, no. 3, 2006,
pp. 286–300., doi:10.1038/sj.mp.4001779.
Ritz, M C, and M J Kuhar. “Psychostimulant Drugs and a Dopamine Hypothesis Regarding
Addiction: Update on Recent Research.” Biochemical Society Symposium , vol. 54, 1993, pp.
51–64.
Rosenkranz, Bernd, et al. “Clinical Pharmacokinetics of Molsidomine.” Clinical
Pharmacokinetics, vol. 30, no. 5, 1996, pp. 372–384., doi:10.2165/00003088-199630050-00004.
Rutherford, Erin C., et al. “Chronic Second-by-Second Measures of l-Glutamate in the Central
Nervous System of Freely Moving Rats.” Journal of Neurochemistry, vol. 102, no. 3, 2007, pp.
712–722., doi:10.1111/j.1471-4159.2007.04596.x.
Santos, Ricardo M., et al. “Brain Nitric Oxide Inactivation Is Governed by the Vasculature.”
Antioxidants &amp; Redox Signaling, vol. 14, no. 6, 2011, pp. 1011–1021., doi:10.1089/ars.
2010.3297.
Santos, Ricardo M., et al. “Evidence for a Pathway That Facilitates Nitric Oxide Diffusion in the
Brain.” Neurochemistry International, vol. 59, no. 1, 2011, pp. 90–96., doi:10.1016/j.neuint.
2011.05.016.
Smith, Bret. “Cellular Neurophysiology LTP.” ANA636. Aug. 2018, Lexington, Kentucky.
Stenslik, Mallory J., et al. “Methodology and Effects of Repeated Intranasal Delivery of
DNSP-11 in a Rat Model of Parkinson's Disease.” Journal of Neuroscience Methods, vol. 251,
2015, pp. 120–129., doi:10.1016/j.jneumeth.2015.05.006.
Tassorelli, C, et al. “The Effects on the Central Nervous System of Nitroglycerin—Putative
Mechanisms and Mediators.” Progress in Neurobiology, vol. 57, no. 6, 1999, pp. 607–624., doi:
10.1016/s0301-0082(98)00071-9.
Teffer, Kate. “Human Prefrontal Cortex: Evolution, Development, and Pathology.” Progress in
Brain Research, vol. 195, 2012, pp. 191–218., doi:10.1107/s0108768107031758/bs5044sup1.cif.
Vincent, S.r., and H. Kimura. “Histochemical Mapping of Nitric Oxide Synthase in the Rat
Brain.” Neuroscience, vol. 46, no. 4, 1992, pp. 755–784., doi:10.1016/0306-4522(92)90184-4.

54

VITA
Name: Victoria A. Scott
Birthplace: Frankfort, Kentucky
Education
2018-2019

M.S., Medical Sciences, University of Kentucky

2015-2017

B.S., Neuroscience, Vanderbilt University

2014-2015

Biology, George Washington University

Employment History
2011-2018

Medical Records Clerk and Medical Assistant, Scott and Jonah, PSC

2015-2017

Research Assistant, Department of Biological Sciences, Vanderbilt University,
Laboratory of Patrick Abbot, Ph.D.

2016-2018

Research Assistant, Department of Neuroscience, Vanderbilt University,
Laboratory of Frank Tong, Ph.D.

2014-2015

Greenhouse Assistant, Department of Biological Sciences, George Washington
University, Supervised by Robert Perry

Scholastic and Professional Honors
2017

Dean’s List, Vanderbilt University, Nashville, Tennessee

2014

Merit Scholarship, George Washington University, Washington, District of
Columbia

Professional Publications
May 25, 2017 Poster Presentation, APS Annual Convention, Boston, Massachusetts titled
“The Vanderbilt Face Memory Test: A Novel and Sensitive Method of
Facial Recognition”

55

